Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8794895 | Ophthalmology Retina | 2017 | 7 Pages |
Abstract
Systemic sunitinib malate may be useful in slowing progression of ocular disease from VHL-associated RCHs. However, significant systemic adverse effects limited its use in this small series, and systemic sunitinib malate may not be safe for treatment of RCHs when used at the doses described in this report. Further studies are required to determine if this medication, used at lower doses with different treatment strategies; other medications in the same class; or drugs directed at multiple targets in the tumor may be safer and more effective for the treatment of advanced VHL-associated RCHs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jared E. MD, PhD, Naima MD, Wai T. MD, PhD, Henry E. MD, Catherine A. MD, PhD, Catherine B. MD, Emily Y. MD,